Boston Scientific Corporation  (BSX)
Other Ticker:  
Price: $51.4200 $-0.40 -0.772%
Day's High: $52.14 Week Perf: 1.84 %
Day's Low: $ 51.54 30 Day Perf: -1 %
Volume (M): 978 52 Wk High: $ 54.17
Volume (M$): $ 50,691 52 Wk Avg: $44.52
Open: $51.59 52 Wk Low: $34.98

 Market Capitalization (Millions $) 74,353
 Shares Outstanding (Millions) 1,446
 Employees 41,000
 Revenues (TTM) (Millions $) 13,046
 Net Income (TTM) (Millions $) 902
 Cash Flow (TTM) (Millions $) 234
 Capital Exp. (TTM) (Millions $) 578

Boston Scientific Corporation
Boston Scientific Corporation is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties, including interventional cardiology, peripheral interventions, neurovascular intervention, electrophysiology, vascular surgery, endoscopy, oncology, urology and gynecology. Since the Company was formed in 1979, it has advanced the practice of less-invasive medicine by providing a broad portfolio of innovative products, technologies and services across a wide range of medical specialties. The Companys products are generally inserted into the human body through natural openings or small incisions in the skin and can be guided to most areas of the anatomy to diagnose and treat a wide range of medical problems. These products help physicians and other medical professionals improve their patients quality of life by providing alternatives to surgery.

   Company Address: 300 Boston Scientific Way Marlborough 1752 MA
   Company Phone Number: 683-4000   Stock Exchange / Ticker: NYSE BSX
   BSX is expected to report next financial results on August 03, 2023.

Customers Net Income grew by BSX's Customers Net Profit Margin fell to

2.76 %

1.79 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


Stock Performances by Major Competitors

5 Days Decrease / Increase
SYK        1.89% 
ABT        0.99% 
DHR        0.01% 
EW        4.52% 
JNJ        2.07% 
KNW        5.98% 
• View Complete Report

The Cooper Companies Inc

The Medical Equipment and Supplies company declared a single digit Top-line elevation, amid the fiscal second quarter of 2023

As a journalist, I have analyzed the financial results of The Cooper Companies Inc in the fiscal second quarter of 2023. The company's revenue managed to inch up by 5.736% to $877.40 million as compared to last year's $829.80 million. This suggests that the company has been able to generate more sales in the current period showcasing a positive trend. However, on the earnings per share front, things were not looking as good. The EPS dropped by -68.63% to $0.80 per share, from $2.55 in the previous quarter.
In comparison to the preceding period, revenue increased by 2.202%, but the profits plummeted drastically, with the EPS decreasing by -52.94% from $1.70. The company's bottom line of $39.800 million fell -68.56% from $126.600 million in the corresponding period a year earlier.

Ra Medical Systems Inc

Ra Medical Systems Inc has failed to turn into profitability despite of epic Surge in revenue in the January to March 31 2023 period

Ra Medical Systems Inc Achieves Strong Revenue Elevations in Q1 2023, But Reports Increased Loss Per Share
Ra Medical Systems Inc, a California-based medical device company that specializes in vascular and dermatology therapy, announced very strong revenue elevations of 844.444% year on year in the fiscal first quarter of 2023. The company's revenue for Q1 2023 was $0.09 million, a significant increase from its revenue of $0.01 million for the same period in 2022. Although the revenue increase is exciting news for Ra Medical, the company also reported an increase in its loss per share.
The loss per share for Q1 2023 was $-24.65, an alarming rise from the preceding quarter's loss per share of $-0.25 and from its previous net income of $0.00 million. The increase in loss per share can be attributed primarily to the company's recent investments in research and development and sales and marketing. These investments were necessary to boost product development and promote commercialization of Ra Medical's products.

Delcath Systems Inc

Delcath Systems Inc announced the deficit has been cut back remarkably, over the January to March 31 2023 period

Investors, get ready to rejoice! Delcath Systems Inc has delivered some impressive results for the first quarter of 2023. The company reported a whopping 57.937% revenue growth to $0.60 million, which has effectively helped to bring down losses to $-0.77 per share. This is a significant improvement from the $-1.00 per share loss reported in the same quarter last year.
Despite a decline in revenue in Q4, it's worth noting that the company managed to improve its EPS from $-0.88 to $-0.77 per share in the most recent quarter. It's always a good indication when a company is able to cut losses and improve profitability.

Haemonetics Corporation

Breathtaking financial reporting period by at the Haemonetics Corporation during the February to April 01 2023 span

Investors in Haemonetics Corporation can expect solid growth and increased earnings based on the company's fiscal fourth quarter 2023 financial results. The medical equipment and supplies company reported an impressive 71.13% increase in income per share to $0.77 compared to the previous year, while revenues grew by 31.706% to $342.13 million.
The company's net earnings also saw a healthy increase of 69.37% to $39.348 million. Although operating margin fell to 13.54%, the net margin actually improved to 11.5%. Operating earnings, however, only improved by 29.97% to $46.336 million.

T2 Biosystems Inc

Extremely challenging financial reporting period for T2 Biosystems Inc during the financial period ending March 31 2023

While the stock market can be a turbulent place, there is one company that has had a rough start to 2023. T2 Biosystems Inc recently reported a substantial decrease in revenue, a net loss per share expansion, and a significant drop in sequential revenue, causing some investors to worry.
But let's take a closer look at what these numbers actually mean. While the Mar 31 2023 report was certainly a disappointment, it's important to remember that these are just one quarter's worth of financials. There are always ups and downs in the stock market, and companies often experience setbacks before bouncing back stronger than ever.


Boston Scientific's Segments
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
Cardiac Rhythm Management
 Segment     of total Revenue
• View Complete Report
  Company Estimates  
  Revenue Outlook
Boston Scientific announced annual revenue outlook on

Earnings Outlook
Boston Scientific Corporation issued annual earnings guidance on

Geographic Revenue Dispersion
United States
Asia Pacific
Other countries


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071